肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2019 ERAS指南：妇产科/肿瘤科围术期管理

2019-03-15 促进术后恢复学会 Int J Gynecol Cancer. 2019 Mar 15.

妇产科肿瘤科围术期管理

2019年3月，促进术后恢复学会(ERAS)更新发布了妇产科/肿瘤科围术期管理指南，本文是对妇产科/肿瘤科围术期管理指南的首次更新，主要建议内容包括入院前信息，教育和咨询，肿瘤预防，术前肠道准备，术前禁食和碳水化合物治疗，静脉血栓栓塞预防，手术部位感染预防，标准麻醉程序，微创手术，液体管理，围术期营养管理，术后肠梗阻预防，患者结局报告等。

中文标题：

2019 ERAS指南：妇产科/肿瘤科围术期管理

英文标题：

Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update.

发布机构：

促进术后恢复学会

发布日期：

2019-03-15

简要介绍：

2019年3月，促进术后恢复学会(ERAS)更新发布了妇产科/肿瘤科围术期管理指南，本文是对妇产科/肿瘤科围术期管理指南的首次更新，主要建议内容包括入院前信息，教育和咨询，肿瘤预防，术前肠道准备，术前禁食和碳水化合物治疗，静脉血栓栓塞预防，手术部位感染预防，标准麻醉程序，微创手术，液体管理，围术期营养管理，术后肠梗阻预防，患者结局报告等。 

拓展指南：与妇产科相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 ERAS指南：妇产科/肿瘤科围术期管理)] GetToolGuiderByIdResponse(projectId=1, id=36c611c001e1984e, title=2019 ERAS指南：妇产科/肿瘤科围术期管理, enTitle=Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update., guiderFrom=Int J Gynecol Cancer. 2019 Mar 15., authorId=null, author=, summary=2019年3月，促进术后恢复学会(ERAS)更新发布了妇产科/肿瘤科围术期管理指南，本文是对妇产科/肿瘤科围术期管理指南的首次更新，主要建议内容包括入院前信息，教育和咨询，肿瘤预防，术前肠道准备，术前禁食和碳水化合物治疗，静脉血栓栓塞预防，手术部位感染预防，标准麻醉程序，微创手术，液体管理，围术期营养管理，术后肠梗阻预防，患者结局报告等。 , cover=, journalId=null, articlesId=null, associationId=732, associationName=促进术后恢复学会, associationIntro=促进术后恢复学会成立于2010年，学会旨在&ldquo;通过开展临床研究，继续教育以及询证实践来发展围术期护理并改善术后恢复。, copyright=0, guiderPublishedTime=Fri Mar 15 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>2019年3月，促进术后恢复学会(ERAS)更新发布了妇产科/肿瘤科围术期管理指南，本文是对妇产科/肿瘤科围术期管理指南的首次更新，主要建议内容包括入院前信息，教育和咨询，肿瘤预防，术前肠道准备，术前禁食和碳水化合物治疗，静脉血栓栓塞预防，手术部位感染预防，标准麻醉程序，微创手术，液体管理，围术期营养管理，术后肠梗阻预防，患者结局报告等。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>妇产科</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=7c2f71c0016693fc" title="2018年法国妇产科医师协会/法国国家卫生管理局《子宫内膜异位症管理指南》解读" target=_blank>2018年法国妇产科医师协会/法国国家卫生管理局《子宫内膜异位症管理指南》解读</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=0abe51c00161252d" title="2018 ACOG委员会意见：青少年和年轻女性进食障碍妇产科管理（No.740）" target=_blank>2018 ACOG委员会意见：青少年和年轻女性进食障碍妇产科管理（No.740）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=42eb51c00155e1e9" title="美国妇产科医师协会《优化产后护理》意见解读" target=_blank>美国妇产科医师协会《优化产后护理》意见解读</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=5fe0a1c00153555b" title="加拿大妇产科医师学会《妊娠期单纯疱疹病毒的管理指南》2017版解读" target=_blank>加拿大妇产科医师学会《妊娠期单纯疱疹病毒的管理指南》2017版解读</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=3cbf61c00152a88a" title="英国皇家妇产科医师协会“产后出血指南（2016版）”要点解读" target=_blank>英国皇家妇产科医师协会“产后出血指南（2016版）”要点解读</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E5%A6%87%E4%BA%A7%E7%A7%91" target=_blank>有关妇产科更多指南</a></ul>, tagList=[TagDto(tagId=155, tagName=妇产科), TagDto(tagId=24882, tagName=肿瘤科), TagDto(tagId=54430, tagName=围术期管理)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=29, categoryName=麻醉疼痛科, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11012, appHits=531, showAppHits=0, pcHits=7579, showPcHits=4334, likes=172, shares=22, comments=13, approvalStatus=1, publishedTime=Sun Mar 31 21:58:33 CST 2019, publishedTimeString=2019-03-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Mar 31 21:58:33 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 18:43:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 ERAS指南：妇产科/肿瘤科围术期管理)])
2019 ERAS指南：妇产科/肿瘤科围术期管理
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1192005, encodeId=0dd11192005a3, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15283017431, createdName=zhangz3303, createdTime=Thu Feb 10 20:51:10 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078262, encodeId=116010e82629d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:44:28 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076355, encodeId=a07410e6355f6, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ca105034, createdName=zhaopeng8933, createdTime=Thu Dec 02 22:23:42 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950245, encodeId=bc8495024579, content=快速康复, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfa12578954, createdName=1259dc82m21暂无昵称, createdTime=Tue Mar 23 07:45:44 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943751, encodeId=91bb943e5159, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cd85462330, createdName=ms4000001495002936, createdTime=Fri Feb 26 16:18:19 CST 2021, time=2021-02-26, status=1, ipAttribution=)]
    2022-02-10 zhangz3303

    学习中

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1192005, encodeId=0dd11192005a3, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15283017431, createdName=zhangz3303, createdTime=Thu Feb 10 20:51:10 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078262, encodeId=116010e82629d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:44:28 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076355, encodeId=a07410e6355f6, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ca105034, createdName=zhaopeng8933, createdTime=Thu Dec 02 22:23:42 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950245, encodeId=bc8495024579, content=快速康复, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfa12578954, createdName=1259dc82m21暂无昵称, createdTime=Tue Mar 23 07:45:44 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943751, encodeId=91bb943e5159, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cd85462330, createdName=ms4000001495002936, createdTime=Fri Feb 26 16:18:19 CST 2021, time=2021-02-26, status=1, ipAttribution=)]
    2021-12-09 一己怀

    受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1192005, encodeId=0dd11192005a3, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15283017431, createdName=zhangz3303, createdTime=Thu Feb 10 20:51:10 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078262, encodeId=116010e82629d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:44:28 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076355, encodeId=a07410e6355f6, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ca105034, createdName=zhaopeng8933, createdTime=Thu Dec 02 22:23:42 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950245, encodeId=bc8495024579, content=快速康复, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfa12578954, createdName=1259dc82m21暂无昵称, createdTime=Tue Mar 23 07:45:44 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943751, encodeId=91bb943e5159, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cd85462330, createdName=ms4000001495002936, createdTime=Fri Feb 26 16:18:19 CST 2021, time=2021-02-26, status=1, ipAttribution=)]
    2021-12-02 zhaopeng8933

    受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1192005, encodeId=0dd11192005a3, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15283017431, createdName=zhangz3303, createdTime=Thu Feb 10 20:51:10 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078262, encodeId=116010e82629d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:44:28 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076355, encodeId=a07410e6355f6, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ca105034, createdName=zhaopeng8933, createdTime=Thu Dec 02 22:23:42 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950245, encodeId=bc8495024579, content=快速康复, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfa12578954, createdName=1259dc82m21暂无昵称, createdTime=Tue Mar 23 07:45:44 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943751, encodeId=91bb943e5159, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cd85462330, createdName=ms4000001495002936, createdTime=Fri Feb 26 16:18:19 CST 2021, time=2021-02-26, status=1, ipAttribution=)]
    2021-03-23 1259dc82m21暂无昵称

    快速康复

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1192005, encodeId=0dd11192005a3, content=学习中, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15283017431, createdName=zhangz3303, createdTime=Thu Feb 10 20:51:10 CST 2022, time=2022-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078262, encodeId=116010e82629d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Dec 09 01:44:28 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076355, encodeId=a07410e6355f6, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8ca105034, createdName=zhaopeng8933, createdTime=Thu Dec 02 22:23:42 CST 2021, time=2021-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950245, encodeId=bc8495024579, content=快速康复, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfa12578954, createdName=1259dc82m21暂无昵称, createdTime=Tue Mar 23 07:45:44 CST 2021, time=2021-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=943751, encodeId=91bb943e5159, content=有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5cd85462330, createdName=ms4000001495002936, createdTime=Fri Feb 26 16:18:19 CST 2021, time=2021-02-26, status=1, ipAttribution=)]
    2021-02-26 ms4000001495002936

    有用

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2018 ACOG实践简报：胎膜早破-临时更新（No.188）

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2018-01-01

2017 FIGO建议：妇产科单独应用米索前列醇（更新版）

国际妇产科联盟(FIGO,International Federation of Gynecology and Obstetrics) · 2017-06-23

宫血宁胶囊妇产科临床应用指导建议

妇产科相关专家组（统称） · 2017-05-26

2015 ACOG/SGO委员会意见：子宫内膜上皮内瘤变（No.631）

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2015-05-02

2014 ACOG 611号委员会共识：预产期评估方法

美国妇产科医师学会(ACOG,American College of Obstetricians and Gynecologists) · 2014-10-31